Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | MELK | Q14680 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 2/20 | 0.49 |
| ▸ | CDK8 | P49336 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.46 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.46 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.46 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203607 | 0.87 | DYRK1A (0.47) | DYRK1AMELKFYNCCNCCDK8 | |
| SCHEMBL244970 | 0.80 | KDR (0.56) | DYRK1AMKNK1MKNK2KDR | |
| SCHEMBL30123115 | 0.79 | DYRK1A (0.46) | DYRK1AFYNCCNCCDK8MAPK1 | |
| SCHEMBL28432597 | 0.78 | MKNK1 (0.49) | CCNCCDK8MKNK1MKNK2FLT3 | |
| SCHEMBL20774126 | 0.78 | KDR (0.55) | DYRK1AMKNK1MKNK2KDR | |
| Ammonia Solution, Strong SCHEMBL18398465 | 0.78 | KDR (0.55) | DYRK1AMKNK1MKNK2KDR | |
| SCHEMBL844281 | 0.78 | LRRK2 (0.61) | CCNCCDK8MKNK1MKNK2LMNA | |
| SCHEMBL29736927 | 0.78 | DYRK1A (0.69) | DYRK1AMKNK1MKNK2MAPTFLT3 | |
| SCHEMBL12535875 | 0.78 | DYRK1A (0.69) | DYRK1AMKNK1MKNK2MAPTFLT3 | |
| SCHEMBL1032066 | 0.77 | MKNK1 (0.44) | DYRK1ACCNCCDK8MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4377305-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | BenevolentAI Cambridge Limited (GB) | 2024-06-05 | — | — | EP | claimed |
| WO-2023007184-A1 | ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | claimed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023107552-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| EP-2312949-B1 | N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426598-B2 | N-heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| WO-2010019391-A1 | N-HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269254-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, BRAF, RET | DYRK1A 675/4885MELK 67/4885FYN 63/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | DYRK1A 3195/4885MELK 3713/4885FYN 3031/4885 |
| US-20160272639-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | DYRK1A 1888/4885MELK 1184/4885FYN 1961/4885 |
| US-20110136863-A1 | N-Heterocyclic M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, OPRM1 | DYRK1A 2488/4885MELK 2232/4885FYN 769/4885 |
| US-20230203030-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, MDM2, XIAP | DYRK1A 1888/4885MELK 1184/4885FYN 1961/4885 |
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | DYRK1A 1834/4885MELK 2977/4885FYN 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.